EP1622571A4 - NUCLEIC ACIDS AND CORRESPONDING PROTEINS CURED 109P1D4 USEFUL IN THE TREATMENT AND DETECTION OF CANCER - Google Patents

NUCLEIC ACIDS AND CORRESPONDING PROTEINS CURED 109P1D4 USEFUL IN THE TREATMENT AND DETECTION OF CANCER

Info

Publication number
EP1622571A4
EP1622571A4 EP04760669A EP04760669A EP1622571A4 EP 1622571 A4 EP1622571 A4 EP 1622571A4 EP 04760669 A EP04760669 A EP 04760669A EP 04760669 A EP04760669 A EP 04760669A EP 1622571 A4 EP1622571 A4 EP 1622571A4
Authority
EP
European Patent Office
Prior art keywords
cancer
useful
detection
treatment
nucleic acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04760669A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP1622571A2 (en
Inventor
Arthur B Raitano
Pia M Challita-Eid
Wangmao Ge
Juan J Perez-Villar
Steven B Kanner
Aya Jakobovits
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agensys Inc
Original Assignee
Agensys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agensys Inc filed Critical Agensys Inc
Publication of EP1622571A2 publication Critical patent/EP1622571A2/en
Publication of EP1622571A4 publication Critical patent/EP1622571A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
EP04760669A 2003-04-30 2004-04-30 NUCLEIC ACIDS AND CORRESPONDING PROTEINS CURED 109P1D4 USEFUL IN THE TREATMENT AND DETECTION OF CANCER Withdrawn EP1622571A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46700203P 2003-04-30 2003-04-30
PCT/US2004/013568 WO2004098515A2 (en) 2003-04-30 2004-04-30 Nucleic acids and corresponding proteins entitled 109p1d4 useful in treatment and detection of cancer

Publications (2)

Publication Number Publication Date
EP1622571A2 EP1622571A2 (en) 2006-02-08
EP1622571A4 true EP1622571A4 (en) 2012-05-02

Family

ID=33435005

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04760669A Withdrawn EP1622571A4 (en) 2003-04-30 2004-04-30 NUCLEIC ACIDS AND CORRESPONDING PROTEINS CURED 109P1D4 USEFUL IN THE TREATMENT AND DETECTION OF CANCER

Country Status (5)

Country Link
EP (1) EP1622571A4 (enExample)
JP (2) JP2007525183A (enExample)
AU (2) AU2004235755A1 (enExample)
CA (1) CA2522994C (enExample)
WO (1) WO2004098515A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7117033B2 (en) 2000-05-08 2006-10-03 Brainsgate, Ltd. Stimulation for acute conditions
US7561919B2 (en) 2002-11-14 2009-07-14 Brainsgate Ltd. SPG stimulation via the greater palatine canal
US8010189B2 (en) 2004-02-20 2011-08-30 Brainsgate Ltd. SPG stimulation for treating complications of subarachnoid hemorrhage
US9233245B2 (en) 2004-02-20 2016-01-12 Brainsgate Ltd. SPG stimulation
US8055347B2 (en) 2005-08-19 2011-11-08 Brainsgate Ltd. Stimulation for treating brain events and other conditions
US20070248535A1 (en) * 2005-02-07 2007-10-25 The Trustees Of Columbia University In The City Of New York Methods to treat or prevent hormone-resistant prostate cancer using siRNA specific for protocadherin-PC, or other inhibitors of protocadherin-PC expression or activity
KR101362681B1 (ko) * 2006-03-31 2014-02-13 알닐람 파마슈티칼스 인코포레이티드 Ｅｇ5 유전자의 발현을 억제하는 조성물 및 억제 방법
JP6236948B2 (ja) * 2013-07-17 2017-11-29 東ソー株式会社 抗体精製用溶出液および当該溶出液を用いた抗体精製方法
US9675796B2 (en) 2013-11-10 2017-06-13 Brainsgate Ltd. Implant and delivery system for neural stimulator
US11497767B2 (en) 2015-02-18 2022-11-15 Enlivex Therapeutics R&D Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11512289B2 (en) 2015-02-18 2022-11-29 Enlivex Therapeutics Rdo Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11000548B2 (en) 2015-02-18 2021-05-11 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11304976B2 (en) 2015-02-18 2022-04-19 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11318163B2 (en) 2015-02-18 2022-05-03 Enlivex Therapeutics Ltd Combination immune therapy and cytokine control therapy for cancer treatment
US11596652B2 (en) 2015-02-18 2023-03-07 Enlivex Therapeutics R&D Ltd Early apoptotic cells for use in treating sepsis
US10857181B2 (en) 2015-04-21 2020-12-08 Enlivex Therapeutics Ltd Therapeutic pooled blood apoptotic cell preparations and uses thereof
US10271907B2 (en) 2015-05-13 2019-04-30 Brainsgate Ltd. Implant and delivery system for neural stimulator
CA3014885A1 (en) 2016-02-18 2017-08-24 Enlivex Therapeutics Ltd. Combination immune therapy and cytokine control therapy for cancer treatment
TWI795381B (zh) 2016-12-21 2023-03-11 比利時商健生藥品公司 作為ｍａｌｔ１抑制劑之吡唑衍生物
ES2966132T3 (es) 2019-02-22 2024-04-18 Janssen Pharmaceutica Nv Forma cristalina de monohidrato de 1-(1-oxo-1,2-dihidroisoquinolin-5-il)-5-(trifluorometil)-(2-(trifluorometil)piridin-4-il)- 1h-pirazol-4-carboxamida
BR112021019799A2 (pt) 2019-04-11 2021-12-07 Janssen Pharmaceutica Nv Derivados contendo anéis de piridina como inibidores de malt1

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002083921A2 (en) * 2001-04-10 2002-10-24 Agensys, Inc. Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001234944A1 (en) * 2000-02-03 2001-08-14 Hyseq, Inc. Novel nucleic acids and polypeptides

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002083921A2 (en) * 2001-04-10 2002-10-24 Agensys, Inc. Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHEN MIN-WEI ET AL: "The emergence of protocadherin-PC expression during the acquisition of apoptosis-resistance by prostate cancer cells", ONCOGENE, NATURE PUBLISHING GROUP, GB, vol. 21, no. 51, 7 November 2002 (2002-11-07), pages 7861 - 7871, XP002599354, ISSN: 0950-9232 *
YOSHIDA K ET AL: "Identification of a Novel Protocadherin Gene (PCDH11) on the Human XY Homology Region in Xq21.3", GENOMICS, ACADEMIC PRESS, SAN DIEGO, US, vol. 62, no. 3, 15 December 1999 (1999-12-15), pages 540 - 543, XP004444711, ISSN: 0888-7543, DOI: 10.1006/GENO.1999.6042 *

Also Published As

Publication number Publication date
WO2004098515A3 (en) 2009-04-30
AU2004235755A1 (en) 2004-11-18
JP2007525183A (ja) 2007-09-06
AU2008212020A1 (en) 2008-09-25
CA2522994A1 (en) 2004-11-18
EP1622571A2 (en) 2006-02-08
CA2522994C (en) 2012-09-25
AU2008212020B2 (en) 2012-05-24
WO2004098515A2 (en) 2004-11-18
JP2011152132A (ja) 2011-08-11

Similar Documents

Publication Publication Date Title
EP1576104A4 (en) NUCLEIC ACIDS AND CORRESPONDING PROTEINS, NAMED 202P5A5, USEFUL FOR THE TREATMENT AND DETECTION OF CANCER
WO2003087306A8 (en) Nucleic acid and corresponding protein entitled 98p4b6 useful in treatment and detection of cancer
EP1622571A4 (en) NUCLEIC ACIDS AND CORRESPONDING PROTEINS CURED 109P1D4 USEFUL IN THE TREATMENT AND DETECTION OF CANCER
AU2002318112B2 (en) Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers
EP1517606A4 (en) NUCLEIC ACID AND CORRESPONDING PROTEIN CURED 193P1E1B USEFUL IN THE TREATMENT AND DETECTION OF CANCER
EP1649002A4 (en) RNA PROCESSING PROTEIN COMPLEXES AND USES THEREOF
AU2002337696A8 (en) Detection of tumor rna in plasma and serum
PT1537140E (pt) Ácido nucleico e proteína correspondente designada 161p2f10b úteis no tratamento e detecção de cancro
EP1590437A4 (en) NUCLEIC ACIDS SUITABLE FOR THE TREATMENT AND DETECTION OF CANCER AND CORRESPONDING PROTEINS NAMED 254P1D6B
EP1372719A4 (en) NUCLEIC ACID AND CORRESPONDING PROTEIN WITH THE NAME 125P5C8 FOR THE TREATMENT AND DETECTION OF CANCER
AU2003301883A8 (en) Modified luciferase nucleic acids and methods of use
AU2001285018A1 (en) Nucleic acids and corresponding proteins entitled 83p2h3 and catrf2e11 useful in treatment and detection of cancer
WO2002083917A8 (en) Nucleic acid and corresponding protein entitled 161p5c5 useful in treatment and detection of cancer
AU2002246708A1 (en) Nucleic acid and encoded zinc transporter protein entitled 108p5h8 useful in treatment and detection of cancer
EP1539805A4 (en) NUCLEIC ACIDS AND CORRESPONDING PROTEINS SAID 101P3A11 OR PHOR-1 FOR THE TREATMENT AND DETECTION OF CANCERS
EP1565200A4 (en) NUCLEIC ACID 24P4C12 AND CORRESPONDING PROTEIN FOR THE TREATMENT AND DETECTION OF CANCER
AU2003268355A8 (en) Localization of human cytomegalovirus nucleic acids and proteins in human cancer cells
EP1578980A4 (en) NUCLEIC ACID AND CORRESPONDING PROTEIN 213P1F11 FOR USE IN THE TREATMENT AND DETECTION OF CANCER
GB0118995D0 (en) Detection of mutations in nucleic acids
EP1399174A4 (en) NUCLEIC ACID AND RELATED PROTEIN, TREATABLE AND DETECTABLE FOR CANCER, NAME 121P1F1
AU2001286541A1 (en) Nucleic acids and corresponding proteins entitled phor1-a11 and phor1-f5d6 useful in treatment and detection of cancer
IL164390A0 (en) Nucleic acid and corresponding protein entitled 98p4b6 useful in treatment and detection of cancer
ZA200501838B (en) Nucleic acid and corresponding protein entitled 98P4B6 useful in treatment and detection of cancer
AU2012244341A1 (en) Nucleic acids and corresponding proteins entitled 191P4D12(b) useful in treatment and detection of cancer
HK1080113A (en) Nucleic acid and corresponding protein entitled 98p4b6 useful in treatment and detection of cancer

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20051129

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL HR LT LV MK

DAX Request for extension of the european patent (deleted)
RIN1 Information on inventor provided before grant (corrected)

Inventor name: JAKOBOVITS, AYA

Inventor name: KANNER, STEVEN, B.

Inventor name: PEREZ-VILLAR, JUAN, J.

Inventor name: GE, WANGMAO

Inventor name: CHALLITA-EID, PIA, M.

Inventor name: RAITANO, ARTHUR, B.

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: AGENSYS, INC.

PUAK Availability of information related to the publication of the international search report

Free format text: ORIGINAL CODE: 0009015

RIC1 Information provided on ipc code assigned before grant

Ipc: C07H 21/04 20060101ALI20090731BHEP

Ipc: C07H 21/00 20060101ALI20090731BHEP

Ipc: C12Q 1/68 20060101AFI20090731BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20120403

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 14/47 20060101ALI20120328BHEP

Ipc: C07K 14/705 20060101AFI20120328BHEP

17Q First examination report despatched

Effective date: 20121029

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20140405